Integra LifeSciences (IART) Q3 2025

Q1 2026 Q4 2025 Q3 2025 Q2 2025

Earnings

Integra LifeSciences delivered a mixed third quarter, posting adjusted EPS of $0.54 that cleared the $0.43 consensus estimate by 24.14%, even as revenue of $402.06 million fell short of the $414.31 million analysts had expected. The top line still gr… Read more Integra LifeSciences delivered a mixed third quarter, posting adjusted EPS of $0.54 that cleared the $0.43 consensus estimate by 24.14%, even as revenue of $402.06 million fell short of the $414.31 million analysts had expected. The top line still grew 5.6% year-over-year, but supply interruptions, including a Medihoney recall and softer private label demand, weighed on results, most visibly in the Tissue Technologies segment, which slipped 0.5% to $109.48 million. The stronger earnings story came from disciplined cost management, with adjusted EBITDA expanding to $78.45 million and margins improving 330 basis points to 19.5%. The company's Codman Specialty Surgical segment provided the clearest bright spot, rising 8.1% to $292.58 million, led by 13.3% organic growth in Neurosurgery. A recent FDA clearance for the CUSA Clarity system in cardiac surgery adds a potential new revenue avenue heading into 2026. Looking ahead, Integra revised full-year 2025 guidance to revenue of $1.62 billion to $1.64 billion and adjusted EPS of $2.19 to $2.24, while its Braintree facility remains on track for a June 2026 production restart.